Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChR
    (1)
  • Adenosine Receptor
    (1)
  • Antiviral
    (1)
  • Dopamine Receptor
    (3)
  • GluR
    (1)
  • Histamine Receptor
    (1)
  • MAO
    (1)
  • NMDAR
    (2)
  • iGluR
    (2)
  • Others
    (2)
Filter
Search Result
Results for "parkinson's syndrome" in TargetMol Product Catalog
  • Inhibitor Products
    13
    TargetMol | Activity
  • Peptides Products
    1
    TargetMol | inventory
Istradefylline
T6552155270-99-8
Istradefylline (KW-6002)(Ki of 2.2 nM) is a selective adenosine A2A receptor (A2AR) antagonist, which is under development in Phase 3 trails. It has been used in trials studying the treatment and basic science of Drug Abuse, Sleep Disorder, Hepatic Impairment, Parkinson's Disease, and Restless Legs Syndrome, among others.
  • $35
In Stock
Size
QTY
Seridopidine
T34616883631-51-4In house
Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
  • $142
In Stock
Size
QTY
AMC-01
T299551047978-71-1In house
AMC-01 has potential antiviral activity and induces dose- and time-dependent inactivation of eIF2-α via phosphorylation of serine residue 51. AMC-01 can be used to study atherosclerosis and Parkinson's syndrome.
  • $350
In Stock
Size
QTY
BDBM50597431
T28367L11629853-49-1In house
BDBM50597431 is an NMDA receptor modulator that may have can be used to study Alzheimer's disease and Parkinson's syndrome.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CBiPES hydrochloride
T22638856702-40-4
CBiPES hydrochloride (CBiPES HCl) is a potent orthosteric modulator of the mGlu2 receptor with an EC50 value of 92.8 nM.CBiPES hydrochloride blocks the action of WT and mGlu(3) receptors.CBiPES hydrochloride can be used to study neurological disorders like epilepsy and Parkinson's syndrome. CBiPES hydrochloride can be used to study neurological disorders like epilepsy and Parkinson's syndrome.
  • $173
In Stock
Size
QTY
TargetMol | Inhibitor Sale
(Rac)-GSK 372475
T68026195875-98-0
(Rac)-GSK 372475 may be investigated for the treatment of Parkinson's syndrome, depression and obesity.
  • $195 TargetMol
In Stock
Size
QTY
DCAT Maleate
T2712757915-90-9
DCAT Maleate is an inhibitor of N-methyl transferases (NMT). DCAT Maleate methylate non-methylated pre-neurotoxins to prevent the formation of Parkinson's syndrome neurotoxins.
  • $1,520
6-8 weeks
Size
QTY
Pramipexole
T1476104632-26-0
Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.
  • $42
In Stock
Size
QTY
TargetMol | Citations Cited
Safinamide
T6651L133865-89-1
Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098μM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8μM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy.
  • $39
In Stock
Size
QTY
Orphenadrine hydrochloride
T1308341-69-5
Orphenadrine hydrochloride (Mephenamin) is a muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
  • $30
In Stock
Size
QTY
Orphenadrine Citrate
T66184682-36-4
Orphenadrine Citrate (Flexon) is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.
  • $34
In Stock
Size
QTY
NNZ 2591
T77995847952-38-9
NNZ 2591, a synthetic analogue of cyclic glycine-proline (cGP), exhibits oral activity and the ability to cross the blood-brain barrier. This compound demonstrates neuroprotective properties following ischemic brain injury and improves motor function in a rat model of Parkinson's disease. NNZ 2591 holds research potential for ischemic brain injury and Angelman syndrome [1] [2] [3].
  • Inquiry Price
Size
QTY
Pramipexole dihydrochloride hydrate
T6951191217-81-9
Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited